Evidence map›Paper›PMID 42400838›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

M13 Bacteriophage pVIII Protein: Display Strategies, Chemical Modification, and Antibacterial Activity Investigations.

Xuanliang Wang, Zongyuan Fan, Ziyue Huang, Zishan Wang, Zhijie Hu, Dairong Li, Huan Peng

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xuanliang WangCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zongyuan FanCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Ziyue HuangCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zishan WangCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zhijie HuCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Dairong LiCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Huan PengCollege of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China. peng_huan@hust.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The excessive and inappropriate use of antibiotics has driven the proliferation of antibiotic-resistant bacterial strains, posing significant challenges to conventional antimicrobial therapies. Endowed with remarkable engineering versatility, the M13 bacteriophage has emerged as a versatile platform for the development of novel antimicrobial strategies. In this chapter, we focused on the major coat protein pVIII of the M13 phage, utilizing genetic engineering and chemical modification approaches to engineer pVIII mutants with tailored surface charge properties. Through comparative analysis of the antibacterial efficacy of phage variants with distinct surface charges, we systematically assessed the influence of positive and negative charge densities on bactericidal activity, aiming to advance the development of innovative antimicrobial therapies.

Indexed as

Anti-Bacterial AgentsBacteriophage M13Capsid ProteinsCell Surface Display TechniquesMicrobial Sensitivity TestsMutationPeptide LibraryAnti-Bacterial AgentsCapsid ProteinsPeptide LibraryAntibacterial activityChemical modificationM13 bacteriophagePhage display

Identifiers

PMID42400838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.